Polymorphisms in COX-2 Gene Influence Prostate Cancer Susceptibility in a Northern Indian Cohort

Archives of Medical Research

Volumn 42, Issue 7, 2011, Pages 620-626

  Mandal, Raju K ^a   Mittal, Rama D ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

COX 2; Inflammation; Prostate cancer

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DIPLOTYPE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; BASE SEQUENCE; COHORT STUDIES; CYCLOOXYGENASE 2; DNA PRIMERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS;

EID: 84855472885     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.10.005     Document Type: Article

References (23)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 5:277-300.
2. Sinha R., Anderson D.E., McDonald S.S., et al. Cancer risk and diet in India. J Postgrad Med 2003, 49:222-228.
3. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-84.
4. De Marzo A.M., Marchi V.L., Epstein J.I., et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999, 155:1985-1992.
5. Edwards S.M., Eeles R.A. Unravelling the genetics of prostate cancer. Am J Med Genet C 2004, 129:65-73.
6. Herschman H.R. Prostaglandin synthase 2. Biochim Biophys Acta 1995, 1299:125-140.
7. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94:252-266.
8. Dubois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J 1998, 12:1063-1073.
9. Singh-Ranger G., Mokbel K. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 2002, 28:729-737.
10. Uefuji K., Ichikura T., Mochizuki H., et al. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 1998, 69:168-172.
11. Panguluri R.C., Long L.O., Chen W., et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004, 25:961-966.
12. Cok S.J., Morrison A.R. The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001, 276:23179-23185.
13. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
14. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
15. Zhang X., Miao X., Tan W., et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005, 129:565-576.
16. Hu Z., Miao X., Ma H., et al. A common polymorphism in the 3' UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 2005, 48:11-17.
17. Gupta S., Srivastava M., Ahmad N., et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42:73-78.
18. Upadhyay R., Jain M., Kumar S., et al. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squamous cell carcinoma. Mutat Res 2009, 663:52-59.
19. Achyut B.R., Ghoshal U.C., Moorchung N., et al. Role of cyclooxygenase-2 functional gene polymorphisms in Helicobacter pylori induced gastritis and gastric atrophy. Mol Cell Biochem 2009, 3211:103-109.
20. Sanak M., Szczeklik W., Szczeklik A. Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol 2005, 116:221-223.
21. Ben Nasr H., Chahed K., Bouaouina N., et al. PTGS2 (COX-2) -765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma. Mol Biol Rep 2009, 36:193-200.
22. Piranda D.N., Festa-Vasconcellos J.S., Amaral L.M., et al. Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer 2010, 10:613.
23. Cheng I., Liu X., Plummer S.J., et al. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 2007, 4:557-561.